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Introduction
============

Testicular germ cell tumors (TGCTs) are the most common malignancy diagnosed in males aged 20 to 39, and the incidence is increasing \[[@REF1]-[@REF3]\]. TGCTs have a tendency to grow rapidly with a high risk of metastatic spread. TGCTs generally present with a palpable testicular mass, yet, less commonly may present with symptoms arising from metastatic disease. Specifically, TGCTs have a propensity to metastasize to retroperitoneal lymph nodes, lungs, liver, bones, and less frequently, to the brain \[[@REF4]\].

The phenomenon of a primary TGCT outgrowing its blood supply and undergoing auto-infarction has been described as a 'burned out' TGCT. The regressed testicular lesion is not appreciable on physical exam, and spontaneous regression occurs without treatment \[[@REF5]\]. Despite the regression of the primary testicular tumor, approximately 50% of 'burned out' primary testicular tumors continue to harbor malignant cells and distant metastatic disease can progress \[[@REF6]-[@REF7]\]. A 'burned out' TGCT can arise, regress, and metastasize within the same testicle. Cases within the literature describe pathological evidence of tumor regression of a testicular mass with a focus of GCT within a clinically unremarkable testicle \[[@REF4],[@REF8]\]. This can lead to difficulty in making a diagnosis as the metastasis can be mistaken for a primary tumor.

Imaging can be helpful in making the diagnosis, with scrotal ultrasonography revealing evidence of a regressed tumor. Possible findings consist of a hypoechoic area, atrophic testicle, or microcalcifications \[[@REF7]-[@REF8]\]. Macroscopic evidence of a fibrotic scar in the parenchyma and microscopic findings of intratubular germ cells or seminomatous foci may be seen on pathological evaluation \[[@REF9]-[@REF11]\].

Of significance, extra-gonadal germ cell tumors (EGCT) are a known entity that also present with biochemistry and histological findings of a germ cell tumor in the absence of primary testicular or ovarian tumor. However, EGCT are differentiated from 'burned out' TGCT by their characteristic midline location, from the pineal gland to the coccyx. Furthermore, in EGCT no radiologic nor pathologic evidence of a primary malignancy is present in the primary reproductive organs \[[@REF12]\].

Chemotherapeutic strategies implemented in the 1970s for the treatment of advanced stage TGCTs represents a paradigm shift to a curable disease \[[@REF13]-[@REF15]\]. Here we discuss a rare case that highlights the challenges of diagnosing a 'burned out' TGCT.

Case presentation
=================

A 24-year-old previously healthy male presented with progressive nausea, vomiting, visual changes, and memory impairment. His only significant finding on history was a strong family history of factor V Leiden mutation. The physical exam was grossly unremarkable. The initial magnetic resonance imaging (MRI) reported a single mass in the right frontal lobe (Figure [1](#FIG1){ref-type="fig"}).

Figure 1Initial Brain MRISingle intra-axial heterogeneously enhancing mass in the inferior aspect of the right frontal lobe.

With high suspicion for primary brain tumor, total resection of the intracranial lesion was performed and revealed a metastatic, poorly differentiated carcinoma with an inconclusive immunohistochemical profile.

Staging investigations with computed tomography (CT) and positron emission tomographic (PET) scans revealed pulmonary and pelvic tumor deposits. A scrotal ultrasound revealed a minimally atrophic right testicle with no further abnormalities detected. A follow-up cranial MRI revealed enhancement in the surgical bed and new metastatic foci (Figures [2](#FIG2){ref-type="fig"}, [3](#FIG3){ref-type="fig"}).

Figure 2MRI One Month Post-ResectionIncreased enhancement in the surgical bed.

Figure 3MRI One Month Post-ResectionNew definite enhancing foci compatible with metastatic foci.

Pathological and imaging findings were consistent with metastatic carcinoma with progressive brain lesions from an unestablished primary focus. At this time the brain lesions were increasingly symptomatic. Further treatment options with chemotherapy and whole brain radiation therapy (WBRT) were discussed with the patient. The patient refused palliative intent chemotherapeutic intervention for unknown primary, but agreed to WBRT with a prescribed dose of 30 gray in 10 fractions delivered. Subsequent to this, additional remote pathological consultation with chromosomal analysis revealed isochrome 12p amplications, consistent with a TGCT. Tumor markers with alpha-fetoprotein (aFP), beta-human chorionic gonadotropin (BhCG), and lactate dehydrogenase (LDH) were not elevated. With evidence supporting the potential for response to chemotherapeutic intervention in TGCT, the patient was started on cisplatin and etoposide, with the plan to include bleomycin in subsequent cycles if his pulmonary function improved \[[@REF14]-[@REF16]\]. Unfortunately the patient's clinical course consisted of progressive brain metastases (Figure [4](#FIG4){ref-type="fig"}), seizures, and pulmonary embolism.

Figure 4MRI Five Months After Initial PresentationMarked progression in a multiple ring-enhancing lesions with vasogenic edema.

He rapidly deteriorated before receiving a full course of treatment and succumbed to his disease only five months after initial presentation. Informed consent was obtained from the patient initially and from the patient\'s family after he passed away.

Discussion
==========

Literature review
-----------------

English publications of 'burned out' TGCT case reports were identified from Medline and EMBASE databases via OVID engine without restrictions on year of publication. The keywords were "germ cell tumor," "burned out phenomenon," and "testicular tumor." Additional studies were identified from reference lists of retrieved papers and review articles. Studies that did not discuss primary testicular origin were excluded. The search yielded 38 results and each abstract was reviewed. A total of 27 articles were thoroughly reviewed and 79 cases of 'burned out' TGCTs were identified. The presenting sites, age of patient, tumor markers, histology, treatments employed, and outcomes were tabulated (Table [1](#TAB1){ref-type="table"}) \[[@REF5], [@REF7]-[@REF8], [@REF17]-[@REF40]\]. 

Table 1Reported Cases of 'Burned Out' TGCTn = number of casesaFP = alpha-fetoproteinBhCG = beta-human chorionic gonadotropinLDH = lactate dehydrogenaseN = normal level+ = elevated levelBEP = bleomycin, etoposide, cisplatinRPLND = retroperitoneal lymph node dissectionNR = not reportedNOS = not otherwise specifiedFirst Author/CitationYear of StudyPresenting/Metastatic SiteAge of PatientTumor MarkersHistologyTreatmentOutcomeBalalaa N \[[@REF17]\]2011Retroperitoneal (n=1)31aFPNNRBEPTreatment responseBhCGNLDH+Balzer BL \[[@REF18]\]2006Retroperitoneal (n=20)17-67 (mean 32)          BhCG+ (n=2)Seminoma (n=26)NRNRWidely disseminated tumor (n=2)Lung and Liver (n=1)Mediastinum (n=1)Other (thyroid, neck thoracic cavity) (n=1)Testicular mass (n=7)Castillo C \[[@REF19]\]2003Retroperitoneal (n=1)25aFP+Mature teratomaBEPInitial clinical responseBhCG+Comiter CV \[[@REF20]\]1995Retroperitoneal (n=1)22-36  NRNRNRNR  Supraclavicular (n=1)Curigliano G \[[@REF21]\]2006Retroperitoneal (n=1)42aFPNSeminomaOrchiectomy, BEP, and RPLNDNRBhCG+LDHNFabre E \[[@REF5]\]2004Testicular (n=1)   32  aFPNSeminomaOrchiectomy and Radiotherapy (30Gy)  Free of disease 16 years after the diagnosis      BhCGNLDHNRetroperitoneal (n=1)  35aFP+Mature teratomaOrchiectomy, BEP plus vincristine, and RPLNDFree of disease 6 years after the diagnosisBhCG+Retroperitoneal (n=1)50aFPNSeminomaOrchiectomy, RPLND, and EPTotal remission 3 years after the diagnosisBhCGNLDH+Retroperitoneal (n=1)17aFPNMature teratomaBEP, retroperitoneal mass resection, and orchiectomyFree of disease 4 years after the diagnosisBhCGNLDHNSupraclavicular (n=1)39aFPNSeminomaBEP followed by salvage chemo (vinblastine, etoposide, ifosfamide, and cisplatin)Total remission 3 years after the diagnosisBhCGNLDHNGeorge SA \[[@REF22]\]2015GIST (n=1)24aFPNMixed GCTOrchiectomyNRBhCGNLDHNGurioli A \[[@REF23]\]2013Retroperitoneal (n=1)35aFPNSeminomaBEP and orchiectomyFree of disease 2 years after the diagnosisBhCGNLDH+Retroperitoneal (n=1)50aFNSeminomaOrchiectomy, vincristine, ifosfamide, bleomycin, and surgical debulking of massFree of disease 4 years after the diagnosisBhCG+Hu B \[[@REF24]\]2015Retroperitoneal (n=1)37aFPNSeminomaNRNRBhCGNLDHNJaber S \[[@REF25]\]2010Retroperitoneal (n=1)32aFPNSeminomaOrchiectomy and surgical removal of the retroperitoneal massNRBhCGNKebapci M \[[@REF26]\]2001Supraclavicular (n=1)22aFPNGCT having choriocarcinoma and probable embryonal cell carcinoma componentsOrchiectomy and BEPNRBhCG+Leleu O \[[@REF27]\]2000Pulmonary (n=1)30aFP+Malignant germ cell tumorOrchiectomy and BEPStable 3 years after the diagnosisBhCG+Lopez  JI \[[@REF28]\]1994Retroperitoneal (n=1)20aFPNChoriocarcinomaOrchiectomy, biopsy of retroperitoneal masses, BEP plus vincristineDeceased 7 months after initial complaintsBhCG+LDH+Mesa H \[[@REF29]\]2009Gastric ulcers (n=1)55aFPNPoorly differentiated adenocarcinoma- further studies revealed seminomaOrchiectomy, vincristine, ifosfamide and cisplatinFree of disease 1 years after the diagnosisBhCGNOnishi K \[[@REF30]\]2014Para-neoplastic neurological syndrome (n=1)41NRSeminomaOrchiectomy and chemotherapyFree of disease 15 months after the diagnosisPatel MD \[[@REF8]\]2007Testicular (n=1)23aFPNMixed GCTOrchiectomyNRBhCGNLDHNPerimenis P \[[@REF31]\]2005Retroperitoneal (n=1)40aFPNSeminomaOrchiectomy, resection of retroperitoneal mass, and radiotherapy to para-aortic nodesFree of disease 2 years after the diagnosisBhCGNLDHNPeroux E \[[@REF32]\]2012Retroperitoneal (n=1)18aFP+Non-seminoma NOSOrchiectomy and chemotherapyFull remissionBhCGNPreda O \[[@REF33]\]2011Retroperitoneal (n=1)43aFPNSeminomaOrchiectomy and chemotherapyFree of disease 5 months after the diagnosisBhCGNLDH+Qureshi JM \[[@REF34]\]2014Retroperitoneal and Pulmonary masses (n=1)20aFPNTeratoma GCTBEP followed by orchiectomy, RPLND, and hepatic mass resectionFree of disease 2 years after the diagnosisBhCG+LDH+Rzeszutko M \[[@REF35]\]2015Spermatic cord (n=1)56aFPNNon-seminoma NOSResection of spermatic cord massFree of disease 6 months post operativelyBhCGNSahoo PK \[[@REF36]\]2013Retroperitoneal (n=1)33aFPNSeminoma vs poorly differentiated carcinoma (seminoma confirmed on IHC)Orchiectomy and BEPPatient under observation at time of publicationBhCGNLDHNSuzuki K \[[@REF37]\]1998Mediastinum (n=1)27aFPNTeratoma GCT and sarcomatous elementsBEPNRBhCGNTasu J \[[@REF7]\]        2003        Retroperitoneal (n=1)23NR        Non-seminoma NOS  (n=3)seminoma (n=2)Non-seminoma NOS: BEP (n=3)Metastatic seminoma: radiotherapy and RPLND (n=1)Seminoma: orchiectomy (n=1)Complete remission (n=3)Free of disease after 5 year follow up (n=1)Free of disease after 7 year follow up (n=1)Retroperitoneal (n=1)35Retroperitoneal (n=1)50Retroperitoneal (n=1)17Supraclavicular (n=1)33Yamamoto H \[[@REF38]\]2007Gastric tumor (n=1)39aFPNSeminomaOrchiectomy and EPFree of disease 2 years after the diagnosisBhCGNLDH+Yucel M \[[@REF39]\]2009Retroperitoneal (n=1)28aFPN'Burned out' testicular tumor NOSOrchiectomy and BEPFree of disease 5 years after the diagnosisBhCGNLDH+Yucel M \[[@REF40]\]2009Prostate (n=1)49aFPNSeminomaOrchiectomy, BEP plus vincristine, and radiotherapy to mediastinum retroperitoneal and pelvic lymph nodesFree of disease 7 years after the diagnosisBhCGN

Results
-------

The sites of symptomatic metastasis identified were retroperitoneal (51.9%), testicular (12.7%), mediastinal (3.8%), pulmonary (3.8%), gastric (3.8%), and others (24.1%) consisting of prostate, supraclavicular, head and neck, and widely disseminated. The average patient age at presentation was 32.7 years old. Tumor markers were not found to be consistently elevated, with only 12.7%, 10.2%, and 5.1% of the cases found to be increased for BhCG, aFP, and LDH respectively. The most common treatment employed was orchiectomy with chemotherapy (57.5%), followed by chemotherapy alone (32.5%). Radiation therapy was utilized in four (10%) cases, all of which were seminoma \[[@REF5],[@REF7],[@REF31],[@REF40]\]. The majority of reported cases had a good treatment response with only one reported death in the literature \[[@REF28]\]. Tabulated case details are summarized in Table [2](#TAB2){ref-type="table"} \[[@REF5], [@REF7]-[@REF8], [@REF17]-[@REF40]\].

Table 2Summary of \'Burned Out\' TGCT CasesNSGCT= non-seminomatous germ cell tumors+BhCG= elevated beta-human chorionic gonadotropin level+aFP= elevated alpha-fetoprotein levelLDH= elevated lactate dehydrogenase levelOrch= orchiectomyPresenting Site of \'Burned Out\' TGCTTotal CasesAge (Mean, Range) +BhCG+aFP+LDHOrch AloneChemo AloneOrch + ChemoRadiation Therapy IncludedTreatment UnknownTreatment Response, Death, Outcome UnknownRetroperitoneal 4132 (17-67)    4922115,1,26 *Seminoma*      4 2   *NSGCT*           Testicular 1033, (23-56)   2  172,0,8 *Seminoma*        1   *NSGCT*     2    0,0.3Mediastinum 330.3 (27-32)    1  2  *Seminoma*            *NSGCT*      1    Pulmonary 327.3 (20-32)     2  2,0,1 *Seminoma*            *NSGCT*       2   Gastric 339 (24-55)    12    *Seminoma*       2    *NSGCT*           Other 1932 (20-49)    13184,0,13 *Seminoma*       11   *NSGCT*      12   Total 7932.7 (17-67)10484131643823,1,51 *Seminoma*   04   4   *NSGCT*   42       *Other/unknown*    2      

Case discussion
---------------

A salient feature of all invasive TGCTs is a gain in material in the short arm of chromosome 12, and is diagnostic if present \[[@REF41]\]. Although the initial pathology revealed a non-diagnostic metastatic tumor, further testing revealed an amplification of chromosome 12p leading to the diagnosis of TGCT. This suggests that the examination of poorly differentiated carcinomas of an unknown primary site using light microscopy and immunohistochemical profiling may be inadequate, and should undergo additional testing modalities with molecular chromosomal analysis \[[@REF41]-[@REF42]\].

The behavior and aggressive nature of the tumor discussed throughout this case combines the complexity of the evolving field of tumor biology and unique patient characteristics. Interestingly, the patient had a confirmed family history of factor V Leiden mutation. It has been suggested that clotting factor polymorphisms such as factor V Leiden are associated with cancer onset and progression. The theoretical mechanism behind such adverse effects stems from the involvement of tissue factor and thrombin in tumor angiogenesis, which is essential for tumor growth and metastasis \[[@REF43]\]. Furthermore, such factors may contribute to a more radio-resistant tumor profile despite advanced diagnostic techniques and treatment modalities. Thus, this case reflects the arising need for further research to explore the dynamic interplay of tumor biology and patient characteristics for targeting tumor response.

Conclusions
===========

This case is presented for its unconventional presentation, rarity of occurrence, and difficulty in diagnosis. It brings forward the discussion of both the commonality of TGCT in young male adults, as well as the anomaly of a 'burned out' TGCT. With unreliable tumor markers, nonspecific symptoms, and pathological findings, the 'burned out' phenomenon accounts for a challenging diagnosis, particularly with the presenting symptom arising from a less common metastatic site. This case adds to the increasing literature on the rare entity of the 'burned out' TGCT, and upon literature review, presents itself as the first reported case presenting with brain metastasis. By establishing a strong foundation of 'burned out' TGCT in the literature leading to familiarity of the diagnostic process, a deeper understanding into medical management may arise.
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Consent for the use of case details with intent of publication was obtained from the individual described in the case study. Consent was discussed and documented by the first author of the case report. As the patient unfortunately was deceased at the time of publication, further written consent was also obtained by the family of the patient.
